ELEDON PHARMACEUT.DL-001
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for C… Read more
ELEDON PHARMACEUT.DL-001 (2TK) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ELEDON PHARMACEUT.DL-001 (2TK) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ELEDON PHARMACEUT.DL-001 - Net Assets Trend (None–None)
This chart illustrates how ELEDON PHARMACEUT.DL-001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ELEDON PHARMACEUT.DL-001 (None–None)
The table below shows the annual net assets of ELEDON PHARMACEUT.DL-001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ELEDON PHARMACEUT.DL-001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ELEDON PHARMACEUT.DL-001 Competitors by Market Cap
The table below lists competitors of ELEDON PHARMACEUT.DL-001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Seetel New Energy Co., Ltd.
TW:7740
|
$139.72 Million |
|
Southeast Cement Co Ltd
TW:1110
|
$139.76 Million |
|
Vivozon Healthcare Inc
KQ:082800
|
$139.77 Million |
|
Ningbo Peace Bird Fashion
SHG:603877
|
$139.78 Million |
|
Fireweed Zinc Ltd
OTCQX:FWEDF
|
$139.60 Million |
|
TVS Srichakra Limited
NSE:TVSSRICHAK
|
$139.59 Million |
|
Stoneridge Inc
NYSE:SRI
|
$139.55 Million |
|
Medeon Biodesign
TWO:6499
|
$139.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ELEDON PHARMACEUT.DL-001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ELEDON PHARMACEUT.DL-001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ELEDON PHARMACEUT.DL-001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ELEDON PHARMACEUT.DL-001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ELEDON PHARMACEUT.DL-001 (2TK) | €- | N/A | N/A | $139.71 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |